Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 18:56:41时区推断·⟳ 抓取 18:59:32·⚡ 决策 08-06 19:02:29 +2m57s·82.0 天前
Pharvaris公布AAE-C1INH研究方法与量表结果，未带来治疗批准或商业化突破
文章披露的是罕见性血管性水肿患者研究方法与量表验证，属于研发流程性进展，当前无已披露治疗获批、里程碑付款或商业放量确认。
📄 原文Investing.com↗ 原文
Pharvaris publishes study on rare angioedema condition
AI momentum stocks tumble as earnings season shakes the tech sector ZUG, Switzerland - Pharvaris (NASDAQ:PHVS) announce…
不做 Pharvaris（PHVS.US）
不做：当前为早期研究发布，未给出商业化突破、订单、授权或可量化财务触发，交易边界不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-06 · 扩散 low · price-in 风险 low ↗
关键理由
- 文章披露的是罕见性血管性水肿患者研究方法与量表验证，属于研发流程性进展，当前无已披露治疗获批、里程碑付款或商业放量确认。
- 该研究未给出明确销售端或收入端的可量化增量口径，且仍处于临床设计/终点评估阶段。
主要风险
- 若无后续关键节点（监管路径、终点阳性数据、商业协议）支撑，短线难形成可执行交易边界。
- 行业面向研究发布的情绪容易在预期外偏差后迅速回归，信号对短周期价格约束较弱。
工具调用 · 历史记录,结果未知(4 种)
- list_mcp_resources · 结果未知
- list_mcp_resource_templates · 结果未知
- read_mcp_resource · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 2,104 字
AI momentum stocks tumble as earnings season shakes the tech sector
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS) announced Wednesday that results from a qualitative study on acquired angioedema due to C1 inhibitor deficiency have been published in Frontiers in Immunology.
The study represents the first in-depth qualitative assessment of AAE-C1INH, a rare disease with no approved therapies for prevention or treatment of attacks. The research examined experiences of people diagnosed with the condition and validated patient-reported outcome measures.
According to the press release statement, interviews with AAE-C1INH patients revealed frequent misdiagnoses, painful swelling attacks, and disruptions to daily functioning. Participants reported impact across physical, emotional, social, and work-related domains, with individuals often unable to carry out routine activities, travel, or maintain employment during attacks. All participants relied on off-label therapies.
The study evaluated patient-reported outcome instruments including Patient Global Impression of Change, Patient Global Impression of Severity, and Patient Global Assessment measures. Results showed these tools are applicable for assessing treatment benefits in AAE-C1INH patients. The study found a PGI-C rating of "better" was deemed meaningful across participants at time points up to four hours post-treatment.
The findings informed the design and endpoint selection of Pharvaris’ ongoing Phase 3 CREAATE study (NCT07266805), which is investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks.
"Despite this, there are currently no therapies approved for the prevention or treatment of AAE-C1INH attacks," said Danny M. Cohn, principal investigator in CREAATE and member of the Department of Vascular Medicine at Amsterdam UMC.
Pharvaris is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema conditions, including hereditary angioedema and AAE-C1INH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS) announced Wednesday that results from a qualitative study on acquired angioedema due to C1 inhibitor deficiency have been published in Frontiers in Immunology.
The study represents the first in-depth qualitative assessment of AAE-C1INH, a rare disease with no approved therapies for prevention or treatment of attacks. The research examined experiences of people diagnosed with the condition and validated patient-reported outcome measures.
According to the press release statement, interviews with AAE-C1INH patients revealed frequent misdiagnoses, painful swelling attacks, and disruptions to daily functioning. Participants reported impact across physical, emotional, social, and work-related domains, with individuals often unable to carry out routine activities, travel, or maintain employment during attacks. All participants relied on off-label therapies.
The study evaluated patient-reported outcome instruments including Patient Global Impression of Change, Patient Global Impression of Severity, and Patient Global Assessment measures. Results showed these tools are applicable for assessing treatment benefits in AAE-C1INH patients. The study found a PGI-C rating of "better" was deemed meaningful across participants at time points up to four hours post-treatment.
The findings informed the design and endpoint selection of Pharvaris’ ongoing Phase 3 CREAATE study (NCT07266805), which is investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks.
"Despite this, there are currently no therapies approved for the prevention or treatment of AAE-C1INH attacks," said Danny M. Cohn, principal investigator in CREAATE and member of the Department of Vascular Medicine at Amsterdam UMC.
Pharvaris is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema conditions, including hereditary angioedema and AAE-C1INH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。